<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720717</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300002466</org_study_id>
    <nct_id>NCT03720717</nct_id>
  </id_info>
  <brief_title>Baclofen as a Perioperative Analgesic Adjuvant</brief_title>
  <official_title>Baclofen as a Perioperative Analgesic Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single, oral dose of baclofen alters&#xD;
      postoperative opioid requirements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain continues to be a significant clinical problem. Use of perioperative&#xD;
      adjuvants has improved postoperative pain control. The GABA-B receptor agonist, baclofen, is&#xD;
      an appropriate drug to trial as such an analgesic adjuvant. Therefore, the investigators will&#xD;
      conduct a study designed to determine whether or not a single, oral dose of baclofen given to&#xD;
      patients undergoing kidney stone surgery will reduce postoperative opioid requirements&#xD;
      measured in the first 24 hours following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">September 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Opioid Requirements</measure>
    <time_frame>From 0 hours post-operatively to 24 hours post-operatively</time_frame>
    <description>Patients Patients' opioid requirements for acceptable pain control will be assessed based on the total oral morphine equivalent needed for post operative pain control.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Opioid Tolerant - baclofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid Tolerant - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid Naive - baclofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid Naive - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen 10mg</intervention_name>
    <description>Baclofen administration pre-operatively</description>
    <arm_group_label>Opioid Naive - baclofen</arm_group_label>
    <arm_group_label>Opioid Tolerant - baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration</description>
    <arm_group_label>Opioid Naive - placebo</arm_group_label>
    <arm_group_label>Opioid Tolerant - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age &gt;= 19 y.o.) scheduled for kidney stone-related surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to baclofen&#xD;
&#xD;
          -  Any condition which might limit appropriate report and treatment of postoperative pain&#xD;
             (e.g., non-English speaking; severe psychiatric disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Mandabach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam B Sturdivant, MPH</last_name>
    <phone>205-934-4042</phone>
    <email>Adamsturdivant@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayesha Bryant, MD, MSPH</last_name>
    <phone>205-996-9669</phone>
    <email>asbryant@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam B Sturdivant, MPH</last_name>
      <phone>205-934-4042</phone>
    </contact>
    <contact_backup>
      <last_name>Ayesha Bryant, MD, MSPH</last_name>
      <phone>205-934-4696</phone>
      <email>asbryant@uab.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Timothy Ness, MD</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

